Attenuation of wound healing processes

• US 5,997,863 A
• Filed: 07/08/1994
• Issued: 12/07/1999
• Est. Priority Date: 07/08/1994
• Status: Expired due to Fees

• Current Assignee: BioMarin Enzymes Inc.
• Original Assignee: IBEX Technologies R And D, Inc.
• Inventors: Vlodavsky, Israel, Broughton, Richard, Bennett, Clark, Zimmermann, Joseph, Danagher, Pamela
• Primary Examiner(s): HOBBS, LISA JOE
• Application Number:
  US08/273,109
• Time in Patent Office: 1,978 Days
• Field of Search: 424/94.61, 424/94.5, 435/201, 435/850, 435/200, 435/232, 514/2, 514/8, 530/825, 536/23.2, 536/23.4
• US Class Current: 424/94.5
• CPC Class Codes: A61K 38/51 Lyases (4)
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: Y10S 530/825 Bacteria

Abstract

Glycosaminoglycans, including heparinases 1, 2 and 3 as well as chondroitinases AC and B from the Gram negative bacteria Flavobacterium heparinum, can be used either separately or in combination to manipulate cell proliferation. In one embodiment, heparinases are administered to degrade heparan sulfate components of the extracellular matrix, thereby allowing the heparin binding growth factors which are stored in the extracellular matrix to migrate to adjacent cells. The mobility of chemoattractant agents, growth factors and cells also can be increased by treating tissues with glycosaminoglycan degrading enzymes, both chondroitinases and heparinases. The enzymatic removal of chondroitin sulfates from cell surfaces effectively increases the availability of growth factor receptors on the cell'"'"'s surface. Selectively removing heparan sulfate from cell surfaces while leaving the extracellular matrix intact, conversely, inhibits cell proliferation by down regulating the cell'"'"'s response to growth factors. This is achieved by targeting heparin or heparan sulfate degrading activities to the cell surface. Targeting the heparin degrading activity can be achieved by genetically engineering a ligand binding functionality into the heparinase proteins, or by physically controlling the localized enzyme concentration through the method of administration.

Claims

1. A method to enhance normal wound healing in a human or an animal comprising

administering to the cells around the wound bacterial glycosaminoglycan degrading lyases selected from the group consisting of heparinase 2 from Flavobacterium heparinum, heparinase 3 from Flavohacterium heparinum, chondroitinase AC from Flavobacterium heparinum, and chondroitinase B from Flavobacterium heparinum, heparinase from Bacteroides strains, heparinase from Flavobacterium Hp206, heparinase from Cytophagia species, chondroitin sulfate degrading lyases from Bacteroides species, chondroitin sulfate degrading lyases from Proteus vulgaris, chondroitin sulfate degrading lyases from Microcossus, chondroitin sulfate degrading lyases from Vibrio species, chondroitin sulfate degrading lyases from Arthrobacter aurescens, and combinations thereof in an amount effective to enhance normal wound healing.

2. The method of claim 1 wherein the cells are contacted with an effective amount of a glycosaminoglycan degrading lyase to promote cell proliferation.

3. The method of claim 1 wherein the cells are contacted with an effective amount of a glycosaminoglycan degrading lyase to inhibit abnormal cell proliferation.

4. The method of claim 1 wherein the cells are selected from the group consisting of muscle cells, fibroblasts, endothelial cells and epithelial cells.

5. The method of claim 3 wherein the lyase is administered to a blood vessel in an amount effective to inhibit restenosis.

6. The method of claim 1 wherein the normal wound healing is accompanied by revascularization.

7. The method of claim 1 wherein the glycosaminoglycan degrading lyase is administered in combination with a delivery vehicle.

8. The method of claim 1 where the glycosaminoglycan degrading lyase is selected from the group consisting of heparinase 2 from Flavobacterium heparinum, heparinase 3 from Flavobacterium heparinum, and combinations thereof.

9. A pharmaceutical composition comprising a bacterial glycosaminoglycan degrading lyase selected from the group consisting of heparinase 2 from Flavobacterium heparinum, heparinase 3 from Flavobacterium heparinum, chondroitinase AC from Flavobacterium heparinum, and chondroitinase B from Flavobacterium heparinum, heparinase from Bacteroides strains, heparinase from Flavobacterium Hp206, heparinase from Cytophagia species, chondroitin sulfate degrading lyases from Bacteroides species, chondroitin sulfate degrading lyases from Proteus vulgaris, chondroitin sulfate degrading lyases from Microcossus, chondroitin sulfate degrading lyases from Vibrio species, chondroitin sulfate degrading lyases from Arthrobacter aurescens, and combinations thereof in combination with a pharmaceutically acceptable carrier for localized administration of an effective amount to enhance normal wound healing.

10. The composition of claim 9 wherein the carrier is a pharmaceutically acceptable carrier for administration topically.

11. The composition of claim 9 wherein the carrier is selected from the group consisting of ointments, polymeric films, gels, microparticulates, microcapsules, liposomes, proteosomes, and lipospheres, implants, transdermal patches, and bandages.

12. The composition of claim 11 wherein the lyase is incorporated into a polymeric matrix.

16. The composition of claim 9 wherein the lyase is selected from the group consisting of heparinase 2 from Flavobacterium heparinum, heparinase 3 from Flavobacterium heparinum, and combinations thereof.

13. A system for enhancing normal wound healing comprising

a purified naturally occurring bacterial glycosaminoglycan degrading lyase in combination with a pharmaceutically acceptable carrier and apparatus for delivery of lyases in combination with the carrier in a dosage effective to enhance normal wound healing.

14. The system of claim 13 wherein the apparatus for delivery is a catheter or endoscope.

15. A pharmaceutical composition comprising a bacterial glycosaminoglycan degrading lyase selected from the group consisting of heparinase 2 from Flavobacterium heparinum, heparinase 3 from Flavobacterium heparinum, chondroitinase AC from Flavobacterium heparinum, and chondroitinase B from Flavobacterium heparinum, in combination with a pharmaceutically acceptable carrier for localized administration of an effective amount to enhance normal wound healing, wherein the lyase is expressed from a recombinant nucleotide sequence in an organism in which it does not naturally occur and the lyase is processed differently than in the organism in which it naturally occurs.

17. A pharmaceutical composition comprising a bacterial glycosaminoglycan degrading lyase selected from the group consisting of heparinase 2 from Flavobacterium heparinum, heparinase 3 from Flavobacterium heparinum, chondroitinase AC from Flavobacterium heparinum, and chondroitinase B from Flavobacterium heparinum in combination with a pharmaceutically acceptable carrier for localized administration of an effective amount to enhance normal wound heating, wherein the glycosaminoglycan degrading lyase is a fusion protein.